In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR)
T cells has demonstrated notable success; nevertheless, further improvements are …

CAR-T cell therapies have consolidated their position over the last decade as an effective
alternative to conventional chemotherapies for the treatment of a number of haematological …

A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence
of these cells in vivo. The expression of memory-associated genes in CAR T cells is linked to …

Despite recent therapeutic advances, metastatic castration-resistant prostate cancer
(mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies have …

Chimeric antigen receptor (CAR) T-cell therapies are a standard of care for certain relapsed
or refractory B-cell cancers. However, many patients do not respond to CAR T-cell therapy or …

Multiple myeloma (MM) remains a challenging hematologic malignancy despite
advancements in chimeric antigen receptor T-cell (CAR-T) therapy. Current targets of CAR-T …

Rheumatoid arthritis (RA) is characterized by processive synovial hyperplasia and abnormal
proliferation of fibroblast-like synoviocytes (FLSs), and can eventually lead to progressive …

Lung cancer remains the most prevalent malignant tumor worldwide and is the leading
cause of cancer‐related mortality. Although immune checkpoint blockade has revolutionized …

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in
achieving durable and potentially curative responses in patients with hematological …

CAR-T therapy has demonstrated effectiveness in hematological malignancies and is now
striding into solid tumor areas. One of the main roadblocks of CAR-T therapy is T cell …